Health Care · Orthopedic, Prosthetic & Surgical Appliances & Supplies

AVNS AVANOS MEDICAL, INC. SEC Filings & Insider Trading Activity 2026

company
CIK 1606498107 filings
Russell 2000

AVNS at a glance

AVANOS MEDICAL, INC. (AVNS, SEC CIK 1606498) filed its latest 10-K annual report on February 24, 2026, a 10-Q quarterly report on May 5, 2026, an 8-K current report on July 30, 2026 and Form 4 insider filings as recently as July 28, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.

  • For the fiscal year ended December 31, 2025 (FY2025), AVANOS MEDICAL, INC. (AVNS) reported revenue of $701.2 million (up 1.9% from FY2024) and a net loss of $72.9 million. Diluted EPS was -$1.57.
  • As of June 30, 2026, 29 institutional investment managers tracked by SignalX reported holding AVANOS MEDICAL, INC. (AVNS) shares worth $480.1 million in 13F-HR filings.

Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).

Revenue · FY2025
$701.2M
+1.9% vs prior year
Insiders · 90 days
0 buys · 0 sells
No open-market trades
13F holders
29 funds
$480.1M · +0 vs prior quarter
Latest 8-K
Jul 30, 2026
Item 1.02 · Item 7.01 · Item 3.01 · Item 3.03 · Item 5.03 · Item 5.01 · Item 2.03 · Item 1.01 · Item 5.02 · Item 2.01

AI 10-Q Quarterly Report Analysis

Latest 10-Q, quarter ended Mar 31, 2026

Management Discussion & Analysis

  • Merger agreement announced April 13, 2026; $25.00-per-share cash consideration
  • Quarterly revenue and YoY change not provided in submitted excerpt
  • Profitability and segment performance figures not provided in submitted excerpt
  • Cash position, operating cash flow, and capital deployment details not provided in submitted excerpt

Risk Factors

  • Newly added merger risk triggered by April 13, 2026 Merger Agreement
  • Regulatory and approval risk from required regulatory clearances and majority stockholder approval
  • Operational disruption risk from employee attrition and customer or supplier delays during merger uncertainty
  • Competitive transaction risk from no-shop restrictions limiting superior acquisition proposals
  • Financial exposure from $37,500,000 termination fee under specified circumstances

AI summary of the AVNS 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K

AI 8-K Current Report Analysis

The most recent material events, by 8-K item

Filed Jul 30, 2026Full analysis →

Item 1.02: Termination of a Material Definitive Agreement

  • Legacy June 24, 2022 credit agreement fully repaid and terminated at merger closing
  • Replacement Credit Agreement entered concurrently, indicating post-merger refinancing of existing debt facilities

Item EX-99.1: Item EX-99.1

  • AIP completed Avanos acquisition for approximately $1.272 billion, converting the company into a privately held business
  • Avanos shareholders received $25.00 cash per share under the merger agreement

Item 7.01: Regulation FD Disclosure

  • Merger closing announced jointly by Avanos Medical and Parent
  • Transaction completion shifts focus to integration, ownership, and post-merger financial reporting

Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule

  • AVNS trading suspended before market open July 27, 2026 following merger completion
  • NYSE delisting removes Common Stock from public exchange trading

Item 3.03: Material Modification to Rights of Security Holders

  • Merger effective time eliminated existing Avanos common-stockholder rights
  • Former shareholders entitled only to merger consideration under the Merger Agreement

Item 5.03: Amendments to Articles of Incorporation or Bylaws

  • Certificate of incorporation and bylaws replaced entirely at merger closing
  • Governance documents now mirror Merger Subsidiary’s pre-closing forms

Item 5.01: Changes in Control of Registrant

  • Merger completion triggered a change in control of Avanos Medical
  • Avanos became a wholly owned subsidiary of Parent

Item 2.03: Creation of a Direct Financial Obligation

  • Item 2.03 links the new financial obligation to the transaction described in Item 1.01
  • Investor impact depends on Item 1.01 terms, including obligation amount, pricing, maturity and use of proceeds

Item 1.01: Entry into a Material Definitive Agreement

  • $675.0M initial term loan borrowed at closing, materially increasing AVANOS’ leverage and interest burden
  • $100.0M delayed-draw term commitments available for 24 months, providing additional acquisition or liquidity capacity

Item 5.02: Departure/Appointment of Directors or Principal Officers

  • Merger-effective board turnover: six incumbent directors resigned, indicating complete governance transition to the acquiring parent
  • David C. Pacitti appointed CEO and director, consolidating executive and board leadership under the post-merger structure

Item 2.01: Completion of Acquisition or Disposition of Assets

  • Merger completed, converting Avanos shares into $25.00 cash per share
  • Approximately $1,200 million paid to Avanos stockholders, eliminating future public-market equity participation
Filed Jul 22, 2026Full analysis →

Item 7.01: Regulation FD Disclosure

  • Stockholders approved and adopted the Merger Agreement at the July 22, 2026 Special Meeting
  • Approval clears the shareholder voting condition for the merger transactions

Item 5.07: Submission of Matters to a Vote of Security Holders

  • Merger approved overwhelmingly: 35,119,793 votes for versus 32,508 against
  • Transaction approval clears the primary shareholder condition for Parent’s acquisition of Avanos

Item EX-99.1: Item EX-99.1

  • Stockholders approved AIP’s acquisition with 99.75% of voted shares supporting the transaction
  • Approval represented 74.96% of total outstanding shares as of June 18, 2026
Filed Jul 15, 2026Full analysis →

Item 8.01: Other Events

  • Merger remains scheduled for July 22, 2026, with the board continuing its unanimous recommendation for the $25.00-per-share transaction
  • Two lawsuits seek to enjoin the merger, while stockholder demand letters allege proxy disclosure deficiencies

AI summaries of AVNS 8-K current reports filed with the SEC. What 8-K item codes mean

SignalX for AVNS

Don't miss the next AVNS filing

  • Alerts as it files. A push when AVNS files an 8-K or an insider trades.
  • Fund moves. Which tracked funds opened, added or cut AVNS, by share count.
  • Ask anything. An AI agent that reads every AVNS filing and answers with sources.

AVNS alerts on your phone. Follow it in the SignalX Android app.

Get it on Google Play

Recent Insider Transactions (Form 4)

Latest reported trades by officers, directors and 10% owners

InsiderTypeDatePrice
Galovan Scott MichaelAJul 27, 2026-
Galovan Scott MichaelDJul 27, 2026-
Delgado SigfridoDJul 27, 2026-
Galovan Scott MichaelDJul 27, 2026$25.00
Delgado SigfridoAJul 27, 2026-
Galovan Scott MichaelDJul 27, 2026$25.00
Delgado SigfridoDJul 27, 2026$25.00
Delgado SigfridoDJul 27, 2026-

Financial Summary
XBRL

Annual financial summary from SEC XBRL data
MetricFY2023FY2024FY2025
Profitability
Revenue-$687.8M$701.2M
Gross Profit$379.7M$381.3M$353.9M
Operating Income--$396.2M-$61.6M
Net Income-$61.8M-$392.1M-$72.9M
Gross Margin-55.4%50.5%
Op. Margin--57.6%-8.8%
Net Margin--57.0%-10.4%
Balance Sheet
Total Assets$1.7B$1.2B$1.1B
Equity-$828.5M$778.2M
ROE--47.3%-9.4%
Per Share
EPS$-1.32$-8.53$-1.57
Cash Flow
Operating CF-$100.7M$74.7M

Source: XBRL data in AVANOS MEDICAL, INC. (AVNS)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →

13F Fund Holdings: Quarterly Trend

Latest: Q2 2026

Aggregate AVNS share value held by 13F filers tracked by SignalX, by quarter.

Quarterly totals table
AVNS shares held by 13F filers tracked by SignalX, by quarter
QuarterFundsTotal value
Q2 202629$480.1M
Q1 202629$284.7M
Q4 202528$248.3M
Q3 202528$271.5M
Q2 202528$269.7M
Q1 202525$225.6M
Q4 202422$235.4M
Position changes: Q1 2026 → Q2 2026
Top Buyers
Top Sellers
Closed Positions

Source: 13F-HR filings on SEC EDGAR (aggregated from 189 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work

AVNS filing archive

AI analysis pages for each 10-K, 10-Q and 8-K

Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4

FormFiling dateAnalysisSEC
SC 13GJul 31, 2026-
8-KJul 30, 2026Analysis-
4Jul 28, 2026--
4Jul 28, 2026--
4Jul 28, 2026--
4Jul 28, 2026--
4Jul 28, 2026--
4Jul 28, 2026--
4Jul 28, 2026--
4Jul 28, 2026--
8-KJul 22, 2026Analysis-
8-KJul 15, 2026Analysis-
8-KJul 2, 2026Analysis-
4May 12, 2026-
4May 12, 2026-
4May 12, 2026-
4May 12, 2026-
4May 12, 2026-
10-QMay 5, 2026Analysis
8-KMay 5, 2026Analysis-
4Apr 24, 2026--
4Apr 24, 2026--
4Apr 16, 2026--
8-KApr 14, 2026Analysis-
4Apr 1, 2026--

Related Health Care companies

All Health Care →

AVNS SEC filings: frequently asked questions

Which institutions hold AVNS stock?

As of June 30, 2026, the largest AVANOS MEDICAL, INC. (AVNS) holders among the 13F filers tracked by SignalX were BlackRock ($185.8 million), State Street Corp ($50.0 million), Vanguard Capital Management LLC ($49.6 million), Millennium Management ($37.9 million), JPMorgan Chase & Co ($27.4 million). 13F-HR reports are filed up to 45 days after each quarter ends.

What was AVNS's revenue in fiscal year 2025?

For the fiscal year ended December 31, 2025 (FY2025), AVANOS MEDICAL, INC. (AVNS) reported revenue of $701.2 million (up 1.9% from FY2024) and a net loss of $72.9 million. Diluted EPS was -$1.57. The figures come from the XBRL data in the 10-K.

What did AVNS report in its latest 8-K?

AVANOS MEDICAL, INC. (AVNS) filed an 8-K on July 30, 2026 reporting Item 1.02 (Termination of a Material Definitive Agreement), Item 7.01 (Regulation FD Disclosure), Item 3.01 (Notice of Delisting or Failure to Satisfy a Continued Listing Rule), Item 3.03 (Material Modification to Rights of Security Holders), Item 5.03 (Amendments to Articles of Incorporation or Bylaws), Item 5.01 (Changes in Control of Registrant), Item 2.03 (Creation of a Direct Financial Obligation), Item 1.01 (Entry into a Material Definitive Agreement), Item 5.02 (Departure/Appointment of Directors or Principal Officers) and Item 2.01 (Completion of Acquisition or Disposition of Assets). Legacy June 24, 2022 credit agreement fully repaid and terminated at merger closing.

What are the latest AVNS SEC filings?

AVANOS MEDICAL, INC. (AVNS) filed its latest 10-K annual report on February 24, 2026, a 10-Q quarterly report on May 5, 2026, an 8-K current report on July 30, 2026 and a Form 4 insider filing on July 28, 2026.

What is AVNS's SEC CIK number?

AVANOS MEDICAL, INC. (AVNS)'s SEC Central Index Key (CIK) is 1606498. EDGAR lists every AVNS filing under that number.

Ask anything about AVNS

The research agent reads AVNS's filings, financials, insider trades and 13F holders, then answers with sources.